ASX:TLXBiotechs
What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders
In July 2026, Telix Pharmaceuticals reported positive early-stage data for its PSMA-targeting therapy TLX591-Tx in advanced prostate cancer, initiated Phase 3 development of TLX250-Tx for clear cell renal cell carcinoma, raised its Fiscal Year 2026 revenue and other income outlook to more than US$1 billion, and entered a collaboration with Regeneron that included an initial US$40 million payment.
These updates indicate Telix is moving multiple radiopharmaceutical therapies into later-stage...

